What is extranodal NK/T-cell lymphoma?
Extranodal NK/T-cell lymphoma (ENKTL) is a rare, aggressive type of non-Hodgkin lymphoma. It develops from natural killer (NK) cells, or less often from cytotoxic T cells, which are white blood cells that normally destroy virus-infected cells.
“Extranodal” means that it usually starts outside the lymph nodes. In about 8 in 10 people, it begins in the nose, sinuses, throat or palate. It was formerly called “nasal type” NK/T-cell lymphoma, and very old texts call it “lethal midline granuloma”.
Almost every case is linked to the Epstein-Barr virus (EBV), the common virus that causes glandular fever. The lymphoma cells carry the virus.
ENKTL grows quickly and destroys tissue, so it needs fast treatment. When it is found early and treated with radiotherapy plus asparaginase-based chemotherapy, many people are cured. Immunotherapy with PD-1 inhibitors has also improved results for disease that comes back.
1. Key facts at a glance
| Feature | Details |
|---|---|
| How common | Rare in Europe and North America (under 1% of lymphomas); much more common in East Asia and parts of Latin America |
| Typical age | Adults, median age about 45-55 |
| Sex | Men are affected about 2-3 times more often than women |
| Main site | Nasal cavity, nasopharynx, sinuses, palate and throat |
| Other sites | Skin, gut, testis, soft tissue, lungs |
| Linked virus | Epstein-Barr virus in nearly all cases |
| Main treatment | Radiotherapy with asparaginase-based chemotherapy for early disease; asparaginase-based chemotherapy, often with a stem cell transplant, for advanced disease |
| Outlook | About 60-80% long-term survival for early nasal disease; much lower for advanced disease |
2. Causes and risk factors
| Factor | Notes |
|---|---|
| Epstein-Barr virus | EBV is found in the lymphoma cells in almost all cases. Most people carry EBV harmlessly, so other factors must also be involved |
| Geography and ancestry | Higher rates in China, Korea, Japan, Southeast Asia, Mexico, Central America and Peru, possibly due to genetic background (HLA types) and patterns of early EBV infection |
| Pesticides and solvents | Linked in some studies |
| Gene changes in the tumour | Acquired changes in genes such as STAT3, JAK3, DDX3X, TP53 and BCOR, and high levels of the immune checkpoint protein PD-L1 |
ENKTL is not inherited and not contagious, even though it is linked to a virus.
3. How does it look?
3.1 In the nose and face
| Feature | What it looks like |
|---|---|
| Nasal mass | A soft, red or grey swelling inside the nose that bleeds easily |
| Ulcers and dead tissue | Ulcers with black or yellow crusts and areas of necrosis (dead tissue), often with a foul smell |
| Tissue destruction | The tumour can erode the nasal septum, the palate or the bones around the nose and eye. A hole in the roof of the mouth may form |
| Facial swelling | Swelling of the cheek, nose or around the eye |
| Nose shape | Collapse of the bridge of the nose in advanced cases |
These changes are often mistaken at first for sinus infection, a fungal infection or granulomatosis with polyangiitis.
3.2 Outside the nose
| Site | Appearance |
|---|---|
| Skin | Purple-red lumps, plaques or ulcers, often on the legs or trunk |
| Gut | Ulcers in the bowel that can bleed or perforate |
| Testis | A painless swollen testicle |
3.3 Under the microscope
| Feature | Description |
|---|---|
| Growth pattern | Lymphoma cells cluster around and invade blood vessel walls (angiocentric and angiodestructive), causing large areas of necrosis |
| Cells | Medium-sized or mixed-size atypical lymphocytes |
| Markers | CD56-positive, cytoplasmic CD3-epsilon positive, surface CD3 negative, and cytotoxic proteins (granzyme B, perforin, TIA-1) |
| EBV test | EBV-encoded RNA (EBER) in the lymphoma cells; this is required for the diagnosis |
| Proliferation | High Ki-67 index |
Because of the necrosis, several deep biopsies are often needed to get enough living tumour tissue.
4. Symptoms
4.1 Nasal and throat disease
| Symptom | Details |
|---|---|
| Blocked nose | Usually on one side at first, not improving with usual treatments |
| Nosebleeds | Repeated or heavy |
| Discharge | Bloody, crusting or foul-smelling discharge |
| Facial pain or swelling | Around the nose, cheek or eye |
| Mouth problems | Ulcers on the palate, loose teeth, difficulty swallowing |
| Eye symptoms | Swelling, double vision or a bulging eye if the tumour reaches the eye socket |
| Voice and hearing | Hoarseness, or blocked ears if the nasopharynx is involved |
4.2 General (B) symptoms
| Symptom | Details |
|---|---|
| Fever | Unexplained, often recurring |
| Night sweats | Drenching |
| Weight loss | More than 10% of body weight in 6 months |
4.3 Other sites
| Site | Symptoms |
|---|---|
| Skin | New lumps or ulcers that do not heal |
| Bowel | Abdominal pain, diarrhoea, bleeding, or sudden severe pain from a perforation |
| Testis | Swelling or heaviness |
4.4 Haemophagocytic syndrome
A small number of people develop haemophagocytic lymphohistiocytosis (HLH), a dangerous over-activation of the immune system. It causes high fever, a large liver and spleen, low blood counts, very high ferritin and liver damage. It needs urgent hospital treatment.
5. Diagnosis
| Test | Purpose |
|---|---|
| Nasal endoscopy and deep biopsy | Takes tissue from the edge of the lesion; often repeated if the first sample shows only necrosis |
| Immunohistochemistry and EBER | Confirms the NK/T-cell type and the presence of EBV |
| PET-CT | Shows how far the lymphoma has spread |
| MRI of the face and sinuses | Shows local spread into bone, eye socket or skull base |
| Plasma EBV DNA | Measures the amount of virus in blood; higher levels predict worse outcome and help track response |
| Bone marrow biopsy | Checks for marrow involvement |
| Blood tests | Full blood count, LDH, liver and kidney function, ferritin |
| Lumbar puncture | In some high-risk cases, to check the spinal fluid |
5.1 Staging and risk scores
Staging uses the Ann Arbor/Lugano system:
| Stage | Meaning |
|---|---|
| Stage I | Lymphoma confined to one area, usually the nose |
| Stage II | Spread to lymph nodes in the neck |
| Stages III-IV | Widespread disease or spread to distant organs |
The PINK score (Prognostic Index of Natural Killer lymphoma) predicts outcome using age over 60, stage III-IV, distant lymph node spread, and non-nasal primary site. Adding blood EBV DNA gives the PINK-E score.
6. Treatment
6.1 Why standard lymphoma chemotherapy does not work well
ENKTL cells often carry a pump protein (P-glycoprotein) that pushes drugs such as doxorubicin out of the cell. For this reason, the standard CHOP regimen works poorly. Modern treatment relies on L-asparaginase or pegaspargase, which starves the lymphoma cells of an amino acid they need.
6.2 Early-stage disease (stages I-II)
Treatment combines radiotherapy with non-anthracycline, asparaginase-based chemotherapy:
| Component | Details |
|---|---|
| Radiotherapy | Usually 50-56 Gy to the nose and surrounding area, using precise techniques (IMRT) |
| Chemotherapy | Given at the same time (concurrent) or before and after radiotherapy (sequential). Examples include P-GemOx, DDGP, VIPD and DeVIC |
| Results | In a Japanese trial of concurrent radiotherapy with DeVIC chemotherapy, about 70% were alive at 2 years; later asparaginase regimens have given similar or better results |
Radiotherapy alone may be used for very limited disease in people unable to have chemotherapy.
6.3 Advanced disease (stages III-IV)
| Option | Details |
|---|---|
| SMILE | Dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide. About 80% respond, but side effects, especially infections, are significant |
| P-GemOx, DDGP or AspaMetDex | Asparaginase-based regimens that are often better tolerated. In a Chinese trial, DDGP gave better results than SMILE |
| Autologous stem cell transplant | Often used to consolidate a complete remission |
| Radiotherapy | To bulky or residual sites |
6.4 Relapsed or refractory disease
| Option | Details |
|---|---|
| PD-1 inhibitors | Pembrolizumab, nivolumab, sintilimab and others. Response rates of about 40-75% have been reported in people whose disease relapsed after asparaginase |
| PD-L1 inhibitors | Sugemalimab is approved in China for relapsed ENKTL |
| Allogeneic stem cell transplant | From a donor; may cure some people who respond to further treatment |
| Clinical trials | Including targeted drugs and EBV-directed cell therapy |
6.5 Supportive care
| Need | Help |
|---|---|
| Nasal care | Saline rinses and crust removal |
| Mouth care | Gentle mouthwashes, dental review before radiotherapy |
| Nutrition | Dietitian support, especially during radiotherapy |
| Infection prevention | Antibiotic and antiviral prophylaxis during intensive chemotherapy |
| Reconstructive surgery | For palate holes or facial damage after cure |
6.6 Possible side effects of treatment
| Treatment | Common side effects |
|---|---|
| Asparaginase or pegaspargase | Allergic reactions, inflammation of the pancreas, liver changes, low fibrinogen and blood clots, high blood sugar |
| Chemotherapy (general) | Low blood counts, infections, tiredness, nausea, hair loss |
| Radiotherapy to the nose | Sore, dry nose and mouth, crusting, loss of taste, skin redness; later, dry mouth, dental problems and, rarely, eye or hormone changes |
| PD-1 inhibitors | Immune-related inflammation of the skin, thyroid, bowel, liver or lungs, which usually responds to steroids |
| Stem cell transplant | Serious infections; after a donor transplant, graft-versus-host disease |
Your team will check blood tests regularly and adjust doses to keep treatment as safe as possible. Report fever, severe abdominal pain, leg swelling or breathlessness straight away.
7. Outlook (prognosis)
| Situation | Approximate outcome |
|---|---|
| Early-stage nasal disease, modern treatment | About 60-80% alive at 5 years |
| Advanced-stage disease | Roughly 30-40% alive at 5 years, depending on treatment and risk score |
| Relapsed disease | Poor historically; PD-1 inhibitors and transplant have improved results for some |
Factors linked to a worse outlook include advanced stage, high blood EBV DNA, high LDH, non-nasal primary site, older age and HLH. Having undetectable EBV DNA after treatment is a good sign.
8. Follow-up
| What | How often |
|---|---|
| Clinic visit and nasal endoscopy | Every 3 months for 2 years, then less often |
| Plasma EBV DNA | At each visit in the first years |
| Scans | PET-CT or MRI at the end of treatment, then if symptoms or EBV DNA rise |
| Late effects checks | Dry mouth, dental problems, eye and hormone changes after radiotherapy |
9. Frequently asked questions
| Question | Answer |
|---|---|
| Can I catch it, or pass it on? | No. EBV is very common and almost never causes lymphoma. The lymphoma itself cannot be passed on |
| Is it the same as nasal cancer? | No. It is a lymphoma (a blood cancer) that happens to grow in the nose. It is treated differently from nasal carcinoma |
| Why did it take so long to diagnose? | Early symptoms look like sinusitis, and the necrosis can make biopsies inconclusive |
| Will my face be changed? | Some tissue loss can occur. Early treatment limits damage, and reconstructive surgery can help |
| Can it come back? | Yes, most relapses happen in the first 2 years, which is why follow-up and EBV DNA tests are frequent then |
Resources
- Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms’, Leukemia, 36(7), pp. 1720-1748.
- Campo, E. et al. (2022) ‘The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee’, Blood, 140(11), pp. 1229-1253.
- Haverkos, B.M. et al. (2016) ‘Extranodal NK/T cell lymphoma, nasal type (ENKTL-NT): an update on epidemiology, clinical presentation, and natural history in North American and European cases’, Current Hematologic Malignancy Reports, 11(6), pp. 514-527.
- Au, W.Y. et al. (2009) ‘Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project’, Blood, 113(17), pp. 3931-3937.
- Kim, S.J. et al. (2016) ‘A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis’, The Lancet Oncology, 17(3), pp. 389-400.
- Suzuki, R. et al. (2011) ‘Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type’, Blood, 118(23), pp. 6018-6022.
- Yamaguchi, M. et al. (2009) ‘Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211’, Journal of Clinical Oncology, 27(33), pp. 5594-5600.
- Kwong, Y.L. et al. (2018) ‘Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma’, Annals of Oncology, 29(1), pp. 256-263.
- Yamaguchi, M. et al. (2011) ‘Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study’, Journal of Clinical Oncology, 29(33), pp. 4410-4416.
- Li, X. et al. (2016) ‘DDGP versus SMILE in newly diagnosed advanced natural killer/T-cell lymphoma: a randomized controlled, multicenter, open-label study in China’, Clinical Cancer Research, 22(21), pp. 5223-5228.
- Kwong, Y.L. et al. (2017) ‘PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase’, Blood, 129(17), pp. 2437-2442.
- Tao, R. et al. (2021) ‘Sintilimab for relapsed/refractory extranodal NK/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)’, Signal Transduction and Targeted Therapy, 6(1), 365.
- National Cancer Institute (2026) Adult Non-Hodgkin Lymphoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.